Cite

HARVARD Citation

    Levin, M. et al. (n.d.). LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults. Open forum infectious diseases. p. S810. [Online]. 
  
Back to record